[Intraperitoneal (Ip) high-dose cisplatinum (CDDP) chemotherapy in patients with advanced ovarian cancer]. 1985

T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010537 Peritoneum A membrane of squamous EPITHELIAL CELLS, the mesothelial cells, covered by apical MICROVILLI that allow rapid absorption of fluid and particles in the PERITONEAL CAVITY. The peritoneum is divided into parietal and visceral components. The parietal peritoneum covers the inside of the ABDOMINAL WALL. The visceral peritoneum covers the intraperitoneal organs. The double-layered peritoneum forms the MESENTERY that suspends these organs from the abdominal wall. Parietal Peritoneum,Peritoneum, Parietal,Peritoneum, Visceral,Visceral Peritoneum,Parametrium,Parametriums
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003536 Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed) Cystadenocarcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
April 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
August 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
August 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
March 1996, Zhonghua fu chan ke za zhi,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
April 1986, Nihon Gan Chiryo Gakkai shi,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
September 2015, Oncology (Williston Park, N.Y.),
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
June 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
June 1985, American journal of obstetrics and gynecology,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
September 2001, Bulletin du cancer,
T Noda, and S Saitoh, and Y Ando, and A Nakanishi, and C Maruya, and S Yoh, and K Hino, and Y Kiyozuka, and M Ichijo
April 2008, The oncologist,
Copied contents to your clipboard!